CN1602900A - Pharmaceutical composition for treating diarrhea, dysentery and eruptive disease - Google Patents
Pharmaceutical composition for treating diarrhea, dysentery and eruptive disease Download PDFInfo
- Publication number
- CN1602900A CN1602900A CNA031514146A CN03151414A CN1602900A CN 1602900 A CN1602900 A CN 1602900A CN A031514146 A CNA031514146 A CN A031514146A CN 03151414 A CN03151414 A CN 03151414A CN 1602900 A CN1602900 A CN 1602900A
- Authority
- CN
- China
- Prior art keywords
- dysentery
- pharmaceutical composition
- diarrhea
- group
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a drug combination for curing diarrhea, dysentery and eruptive disease, composed of radix angelicae formosanae, rhizoma atractylodis, rhizoma graminei, Asarum sieboldii, Piper cubeba, Herba Centipedae, etc, and able to have better curative effect on diarrhea, dysentery and eruptive disease.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition, relate in particular to a kind of pharmaceutical composition for the treatment of diarrhea, dysentery and eruptive disease.
Background technology
Diarrhea, dysentery and eruptive disease (heatstroke) are a kind of commonly encountered diseases, especially in the weather summer of heat, the mainly focus that is caused by the dirty grade of a kind of poison.The described diarrhea of medical science, dysentery, acute gastroenteritis, the intestines and stomach type flu (flu the intestines and stomach type), bacillary dysentery and the colitis etc. that roughly comprise modern medicine, clinical manifestation is stomachache, diarrhoea or tenesmus, have with nausea and vomiting etc., and the traditional Chinese medical science is referred to as the disease of eruptive disease, similar with " heatstroke " of modern medicine, be main clinical manifestation with chest distress, nausea and vomiting, fever and headache even faintness syncope.Chinese medical discrimination is cold-damp, cold and heat and cold acute filthy disease.The medicine that is commonly used to treat at present is mainly at single disease treatment, can not at three diseases therapeutical effect be arranged simultaneously; Western medicine commonly used such as norfloxacin, furazolidone, oxytetracycline etc., but Western medicine is to the no definite curative effect of heatstroke, and the while takes for a long time, cures the symptoms, not the disease.Still there is not simultaneously specially Chinese patent drugs for treatment medicine in the market at diarrhea, dysentery and eruptive disease (heatstroke).Do not appear in the newspapers as yet in the medicine document at home and abroad by the dirty heatstroke that causes of poison, dysentery and eruptive disease (heatstroke).
Summary of the invention
The object of the present invention is to provide a kind of pharmaceutical composition that can treat diarrhea, dysentery and eruptive disease (heatstroke) simultaneously.
A kind of pharmaceutical composition for the treatment of diarrhea, dysentery and eruptive disease of the present invention is made up of the medicine of following weight percentage ratio: Radix Angelicae Dahuricae 15-25%, Rhizoma Atractylodis 5-10%, Rhizoma Acori Graminei 5-10%, Herba Asari 4-9%, Fructus Piperis Longi 3-8%, Herba Centipedae 3-8%, Fructus Gleditsiae Abnormalis 5-10%, Realgar 5-10%, Flos Caryophylli 3-8%, Sal Nitri 4-9%, Alumen 15-25%, Borneolum Syntheticum 0.5-2%; The optimum weight percentage ratio of pharmaceutical composition of the present invention is: the Radix Angelicae Dahuricae 17.4%, Rhizoma Atractylodis 8.7%, Rhizoma Acori Graminei 8.7%, Herba Asari 6.9%, Fructus Piperis Longi 5.2%, Herba Centipedae 5.2%, Fructus Gleditsiae Abnormalis 8.7%, Realgar 8.7%, Flos Caryophylli 5.2%, Sal Nitri 6.9%, Alumen 17.4%, Borneolum Syntheticum 1.0%.
The present invention can further be processed into tablet or capsule, preferentially makes tablet.
Radix Angelicae Dahuricae dispeiling pathogenic wind and removing dampness in the pharmaceutical composition of the present invention, [Bencao Jingshu] are said its " treatment wind chronic diarrhea ", and [book on Chinese herbal medicine justice] is also called it and " controlled the good agent of chronic diarrhea ".The modern pharmacology test shows that this product has certain inhibitory action to escherichia coli, dysentery (Song Shi) bacillus, Bacillus typhi, vibrio cholera etc.; The Rhizoma Atractylodis the spleen strengthening and damp drying, resolving depression is warded off dirty, and kind stopping vomiting is told, diarrhea, diseases such as dysentery, [book on Chinese herbal medicine is just] tastes meaning: " Rhizoma Atractylodis, its warm in nature loosing ... go abdominal distnetion painful, the cholera vomiting "; Rhizoma Acori Graminei is regulated the flow of vital energy, and the wind that looses dries, and is longer than repelling foulness with aromatics especially, and [Japan hanako materia medica] claims it " to end cardiac and abdominal pain, cramp caused by acute vomiting and diarrhea ".[Compendium of Materia Medica] says it, and " it is dead to control the attacked by pestiferous factors soldier.(annotate: similar heatstroke is fainted) "; Herba Asari is arrogated to oneself expelling wind and cold, can end the deficiency and coldness vomiting, inappetence.Modern pharmacological research confirms that this product volatile oil has inhibitory action to gram-positive bacterium; The Fructus Piperis Longi warming spleen and stomach for dispelling cold, promoting the circulation of QI pain relieving, the kind trusted subordinate's cold type of pain of ending, vomiting, borborygmus diarrhea, cold-dysentery.The quintessence oil that the modern pharmacology evidence proposes from this product all has inhibitory action to escherichia coli, dysentery bacterium, white and staphylococcus aureus etc., and the damp eliminating of Herba Centipedae function expelling wind and cold cures mainly eruptive disease stomachache, and [medical center bun will] says that its can " dysentery relieving "; The gleditsia officinalis speciality is sensible, and [book on Chinese herbal medicine is stated] claims it " to cure mainly middle summer-heat spasm ", and [Mingyi Bielu] says its " treatment distention and fullness in the abdomen ", and [property of medicine opinion] called it and controlled " abdominal pain "; The Flos Caryophylli warming middle-JIAO to send down the adverse QI, kind stopping vomiting is told, dysentery, trusted subordinate's cold type of pain, [Kaibao Bencao] says its " warming the spleen stomach, only cholera." modern pharmacological research confirms that this product all has inhibitory action to escherichia coli, dysentery bacterium, Bacillus typhi etc.; The Sal Nitri merit is arrogated to oneself and is cleansed the intestines and stomach, to the abdominal distention due to the eating accumulation, and stomachache, the stool dysentery is not well to wait disease that good result is all arranged; Alumen function dampness removing and diarrhea-relieving has Detoxication again, and [Sheng Nong's herbal classic] tastes meaning: Alumen " main cold and heat dysentery ".Modern pharmacological research confirms that this product has inhibitory action to dysentery bacterium, Bacillus typhi etc.; The Realgar merit is arrogated to oneself the dampness detoxifcation of dispeling the wind, and [Mingyi Bielu] claims it to cure mainly " attacked by pestiferous factors stomachache ", and [Japan hanako materia medica] says its " haze miasma ".The modern pharmacology evidence has killing action to staphylococcus aureus, Bacillus proteus etc.; The kind logical all keys of Borneolum Syntheticum, [Bencao Jingshu] say it " can ward off all evilnesses ... so main trusted subordinate's pathogen.”
Test 1: pharmaceutical composition of the present invention is to the drug effect of treatment diarrhea
1, normal intestinal propulsion exercise test: get 50 of white mice, body weight 20 ± 2g, fasting 20 hours, group (0.6g/kg) when being divided into medicine low dose group of the present invention (0.15g/kg), middle dosage group (0.3g/kg), high agent at random.Five groups of blank groups etc., every group of 10 white mice, each organized perfusion after 30 minutes, and the suspension that mouse gavaging is last by 5% charcoal and 10% arabic gum is made was put to death mice after 20 minutes, cut the abdominal cavity, the clip upper end is to pylorus, and the lower end is to the ileocecus intestinal tube, and the total length of measuring intestinal tube is " a small intestinal total length ", distance from pylorus to the prepared Chinese ink forward position is as " prepared Chinese ink is at the enteral advance distance ", thus the propelling rate of reckoning carbon powder.
Medicine of the present invention is to the experiment of normal intestinal propulsion rate: studies show that medical instrument of the present invention has obvious inhibition intestinal propulsion function, each dosage group and blank group more all have statistical significance (P＜0.01), see table 1 for details.
Table 1 medicine of the present invention is to normal intestinal propulsion motion effects
Group example number propelling rate (%)
Matched group 10 55.78 ± 1.09
Low dose group 10 49.18 ± 1.49
*
Middle dosage group 10 44.62 ± 2.52
*
High dose group 10 40.61 ± 1.57
*
*Each treatment group is compared P＜0.01 with the blank group.
2, to advancing ergogenic intestinal motility test: medication is the same, beyond the animal grouping is the same, add one group of simple neostigmine matched group again, each is organized administration and irritates stomach with methyl neostigmine 2mg/kg after 20 minutes, irritate carbon powder arabic gum juice after 10 minutes, put to death mice after 10 minutes, the same method is measured prepared Chinese ink in the intestinal propulsion rate.
Obviously the mouse small intestine motion that causes of antagonism neostigmine is hyperfunction for pharmaceutical composition of the present invention, with matched group than equal significant difference, see table 2 for details.
Table 2 pharmaceutical composition of the present invention influences the superfunction of neostigmine induced mice small intestinal
Group example number charcoal end propelling rate (%)
Blank group 10 53.62 ± 2.06
Matched group 10 67.46 ± 2.44
Low dose group 10 47.36 ± 1.6
*
Middle dosage group 10 43.63 ± 2.04
*
High dose group 10 42.88 ± 1.84
*
*: compare with blank group, matched group and to have significant difference (P＜0.01).
Test 2: the anti-diarrhea effect test of pharmaceutical composition of the present invention
Get 50 of above healthy mices, body weight 20 ± 2g, male and female half and half are divided into 5 groups at random, sub-cage rearing, every Mus one cage.Medicine of the present invention is made into 12mg/kg, 6mg/kg, 3mg/kg, after the fasting 12 hours, basic, normal, high dosage group is pressed 0.15g/kg, 0.3g/kg respectively, 0.6g/kg irritates stomach, the blank group waits the normal saline of capacity, each treated animal is given 8% Folium Sennae suspension oral gavage 0.5mg/20g after 1 hour, under the mouse cage of paper shop, make 24 hours muck countings immediately, and record dehumidifying excrement number of animals.
Each medication group of experimental result all can obviously make mice discharge the minimizing of muck number, compares with matched group, and statistical significance is all arranged, and pharmaceutical composition high dose group wherein of the present invention is more obvious.
Table 3 medicine of the present invention is to diarrhoea influence due to the Folium Sennae
Group example number muck is counted dehumidifying excrement number of animals
Matched group 10 6.7 ± 1.88 10
Low dose group 10 1.5 ± 1.08
*8
Middle dosage group 10 0.9 ± 0.87
*6
High dose group 10 0.4 ± 0.51
*4
*: P＜0.01 compared with the control
Experiment shows that pharmaceutical composition of the present invention has remarkable anti-diarrhea effect to diarrhoea due to the Folium Sennae.
Test 3: the analgesic activity experimentation of pharmaceutical composition of the present invention
Get 50 healthy mices, body weight 18-22g male and female half and half, be divided into 5 groups at random, 10 every group, the high, medium and low dosage group of medicine of the present invention is 0.15g/kg, 0.3g/kg, 0.6g/kg, aspirin is 0.3g/kg, normal saline is irritated in contrast, and administration is after 30 minutes, and each Mus lumbar injection 0.5% acetic acid 0.2ml/ only, observe writhing response in 10 minutes (abdominal part indent, stretching, extension hind leg, arm are raised) number of times.
Experimental result shows that medicine Dichlorodiphenyl Acetate of the present invention causes that the mouse writhing reaction times is respectively 22.2 ± 11.65,17.1 ± 10.37,11.1 ± 5.42, and comparing with the blank group all has statistical significance, but effect will be weaker than the aspirin group, sees table 2 for details.
Table 4 medicine of the present invention is to the mouse writhing reaction times
Group example number is turned round the body number of times
Blank group 10 31.1 ± 9.33
Low dose group 10 22.2 ± 11.65
*△
Middle dosage group 10 17.1 ± 10.37
*△
High dose group 10 11.1 ± 5.42
*△
Aspirin group 10 8.3 ± 6.27
*
*: comparing with matched group all has statistical significance P＜0.01.
△: with aspirin group contrast P＜0.01.
Conclusion:, show that medical instrument of the present invention has certain analgesic effect though the analgesic effect of medicine of the present invention all has statistical significance not as good as aspirin with each dosage group of blank group comparison.
The specific embodiment
Embodiment 1: the prescription of the pharmaceutical composition of present embodiment is as follows:
The Radix Angelicae Dahuricae 17.4% Rhizoma Atractylodis 8.7%
Rhizoma Acori Graminei 8.7% Herba Asari 6.9%
Fructus Piperis Longi 5.2% Herba Centipedae 5.2%
Fructus Gleditsiae Abnormalis 8.7% Realgar 8.7%
Flos Caryophylli 5.2% Sal Nitri 6.9%
Alumen 17.4% Borneolum Syntheticum 1.0%
Take by weighing each medicine by above-mentioned prescription, wherein Realgar water is flown into impalpable powder.Remaining pulverize separately becomes fine powder, fully packing behind the mixing.
Embodiment 2: the prescription of the pharmaceutical composition of present embodiment is as follows:
The Radix Angelicae Dahuricae 23% Rhizoma Atractylodis 6%
Rhizoma Acori Graminei 6.5% Herba Asari 5%
Fructus Piperis Longi 4% Herba Centipedae 4%
Fructus Gleditsiae Abnormalis 7% Realgar 6%
Flos Caryophylli 7% Sal Nitri 7.5%
Alumen 23% Borneolum Syntheticum 1.5%
Take by weighing each medicine by above-mentioned prescription, wherein Realgar water is flown into impalpable powder.Remaining pulverize separately becomes fine powder, fully packing behind the mixing.
Embodiment 3: the prescription of the pharmaceutical composition of present embodiment is as follows:
The Radix Angelicae Dahuricae 15.5% Rhizoma Atractylodis 9%
Rhizoma Acori Graminei 9% Herba Asari 5%
Fructus Piperis Longi 7% Herba Centipedae 7%
Fructus Gleditsiae Abnormalis 7% Realgar 8%
Flos Caryophylli 7% Sal Nitri 8%
Alumen 15.5% Borneolum Syntheticum 2%
Take by weighing each medicine by above-mentioned prescription, wherein Realgar water is flown into impalpable powder.Remaining pulverize separately becomes fine powder, fully packing behind the mixing.
The medicine of the foregoing description gained further can also be processed into capsule or tablet.
Claims (2)
1, a kind of pharmaceutical composition for the treatment of diarrhea, dysentery and eruptive disease is characterized in that being made by the following weight proportion raw material:
Radix Angelicae Dahuricae 15%-25% Rhizoma Atractylodis 5%-10%
Rhizoma Acori Graminei 5%-10% Herba Asari 4%-9%
Fructus Piperis Longi 3%-8% Herba Centipedae 3%-8%
Fructus Gleditsiae Abnormalis 5%-10% Realgar 5%-10%
Flos Caryophylli 3%-8% Sal Nitri 4%-9%
Alumen 15%-25% Borneolum Syntheticum 0.5%-2%
2, a kind of pharmaceutical composition for the treatment of diarrhea, dysentery and eruptive disease according to claim 1 is characterized in that being made by the following weight proportion raw material:
The Radix Angelicae Dahuricae 17.4% Rhizoma Atractylodis 8.7%
Rhizoma Acori Graminei 8.7% Herba Asari 6.9%
Fructus Piperis Longi 5.2% Herba Centipedae 5.2%
Fructus Gleditsiae Abnormalis 8.7% Realgar 8.7%
Flos Caryophylli 5.2% Sal Nitri 6.9%
Alumen 17.4% Borneolum Syntheticum 1.0%
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA031514146A CN1602900A (en) | 2003-09-29 | 2003-09-29 | Pharmaceutical composition for treating diarrhea, dysentery and eruptive disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA031514146A CN1602900A (en) | 2003-09-29 | 2003-09-29 | Pharmaceutical composition for treating diarrhea, dysentery and eruptive disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1602900A true CN1602900A (en) | 2005-04-06 |
Family
ID=34659927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA031514146A Pending CN1602900A (en) | 2003-09-29 | 2003-09-29 | Pharmaceutical composition for treating diarrhea, dysentery and eruptive disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1602900A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103877545A (en) * | 2014-03-15 | 2014-06-25 | 青岛绿曼生物工程有限公司 | Traditional Chinese medicinal composition for treating poultry diarrhea and preparation method thereof |
-
2003
- 2003-09-29 CN CNA031514146A patent/CN1602900A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103877545A (en) * | 2014-03-15 | 2014-06-25 | 青岛绿曼生物工程有限公司 | Traditional Chinese medicinal composition for treating poultry diarrhea and preparation method thereof |
| CN103877545B (en) * | 2014-03-15 | 2016-08-17 | 青岛众志合才智能科技有限公司 | Chinese medicine composition for the treatment of avian dysentery and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1899505A (en) | Medicine composition for clearing heat and purging-fire | |
| CN1857681A (en) | Gastropathy treating preparation and its preparing process | |
| CN101850008A (en) | Bacillus Ling oral liquid and preparation method thereof | |
| CN101040924A (en) | Chinese traditional medicine for treating fowl coccidiosis and the preparing method thereof | |
| CN1210047C (en) | Medicine for treating cold and preparation method thereof | |
| CN1127648A (en) | Chinese medicine composition with antipyretic and antidote functions and use thereof | |
| CN104491052B (en) | Traditional Chinese medicine composition for treating rheumatic and rheumatoid arthritis and preparation method thereof | |
| CN1857416A (en) | Chinese medicine composition with functions of expelling surficial evils and clearing away head and toxic materials and its preparing method and application | |
| CN1954866A (en) | Medicine for treating odontopathy and its preparation method | |
| CN1806821A (en) | Rhinitis-treating medicine | |
| CN1943757A (en) | A Chinese traditional medicinal composition for treatment of hemicrania and its preparation method | |
| CN1927279A (en) | Chinese medicine composition for treating skin disease | |
| CN1943758A (en) | A Chinese traditional medicinal composition for treatment of rheumatism and its preparation method | |
| CN1602900A (en) | Pharmaceutical composition for treating diarrhea, dysentery and eruptive disease | |
| CN1051009C (en) | Chinese drug for treating chronic colitis | |
| CN1600333A (en) | Painkiller | |
| CN104523897A (en) | Enteroclysis medicine composition for treating piglet epidemic diarrhea | |
| CN1931276A (en) | Headache treating Chinese medicine composition and its prepn process | |
| CN1308017C (en) | Medicine composition for treating eliminateion, dysentery and eruptive disease | |
| CN1943632A (en) | A kind of medicine for treating infant cold and its preparing method | |
| CN100342877C (en) | Medicine for promoting qi circulation, resolving food retention, benefiting stomach and stopping pain and preparation process thereof | |
| CN1261125C (en) | Chinese herbal medicine and for treating acute rhinitis and chronic rhinitis as well as its preparing method | |
| CN101209315A (en) | Chinese medicinal injection with antimicrobial and anti-inflammation, milk-smoothing and mass-dissipating efficacy | |
| CN1915400A (en) | Medication for treating symptoms of the illness of nasosinusitis | |
| CN1876087A (en) | A medicament for treating tension headache and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |